First dose has been administered in the multiple-center study  BN-Brachyury for the treatment of chordoma received FDA Orphan Drug Designation in May 2018 COPEN...

Castle Biosciences, Inc., the skin cancer diagnostics company providing molecular diagnostics to improve cancer management decisions, today announced the presentation...

Maastricht, The Netherlands, October 25, 2018 / B3C newswire / -- Cristal Therapeutics, a clinical stage pharmaceutical company developing unique nanomedicines for th...

UPPSALA, Sweden, October 29, 2018 (Newswire.com) - OssDsign AB, the Swedish designer, manufacturer and distributor of regenerative implants for cranial and facial rec...

Phase III MAIA study of daratumumab in combination with lenalidomide and dexamethasone in front line multiple myeloma met the primary endpoint (PFS) at a pre-plann...

Nearly 1 in 4 patients with advanced cancer, treated at Comprehensive Cancer Care Network (NCCN) centres in the US, are receiving innovative drugs matched to DNA muta...

Groningen, The Netherlands, October 22, 2018 / B3C newswire / -- Polyganics, a medical technology company developing, manufacturing and commercializing bioresorbable ...

Phase III CASSIOPEIA study of daratumumab in combination with bortezomib, thalidomide and dexamethasone in front line multiple myeloma met the primary endpoint of ...